PARAINFLUENZA VIRUS TYPE 3
Purified Virus Lysate

PRODUCT DESCRIPTION:

Parainfluenza Virus is an enveloped, negative-sense single-stranded RNA virus with a diameter of approximately 150 to 250 nm.

Parainfluenza Virus Type 3 is propagated in the LLC-mk2 cell line.

This virus is purified using sucrose density gradient ultracentrifugation, disrupted in the presence of 0.5% Triton X-100 non-ionic detergent/0.6 M KCl, and heat inactivated.

Viral lysate is usually sold in a vial containing 1.0 mg of protein, and is shipped on dry ice. Protein concentrations generally range from 0.5 to 3.0 mg/mL.

Custom orders are available, including specific buffer formulations and package sizes.

INTENDED USE:

This product is intended for research, product development, quality assurance testing, or further manufacturing use.

Viral lysates can be utilized as an antigen, as a source for the purification of viral proteins, or for the detection of viral antibodies. Applications include:

- Immunodetection of antibodies to Parainfluenza Virus using solid-phase enzyme immunoassays (EIA)
- Western blot
- Dot blot
- Other protein-based assays

ETIOLOGIC STATUS/BIOHAZARD TESTING:

Parainfluenza Virus is a Biosafety Level 2 organism.

Viral inactivation is verified for every lot of lysate by the absence of viral growth in validated tissue culture based infectivity assays.

PRECAUTIONS:

USE UNIVERSAL PRECAUTIONS when handling this product!

Viral lysate has been treated by a method validated to be effective for virus inactivation. However, no method can be guaranteed 100% effective.

This material should be handled as if capable of transmitting infectious agents.

RECOMMENDED STORAGE:

Viral lysate is stable for at least one year when stored at -65°C or below.

To avoid repeat freeze-thaws, which could negatively impact product performance, viral lysate should be stored in aliquots upon receipt.

DO NOT USE IN HUMANS. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act, or for any other product intended for administration to humans.